Montelione Gaetano T, Szyperski Thomas
Rutgers University, Center for Advanced Biotechnology and Medicine, Department of Molecular Biology and Biochemistry, Robert Wood Johnson Medical School, Piscataway, NJ 08854-5638, USA.
Curr Opin Drug Discov Devel. 2010 May;13(3):335-49.
Rational drug design relies on the 3D structures of biological macromolecules, with a particular emphasis on proteins. The structural genomics-based high-throughput structure determination platforms established by the Protein Structure Initiative (PSI) of the National Institute of General Medical Science (NIGMS) of the NIH are uniquely suited to provide these structures. NMR plays a critical role in structure determination because many important protein targets do not form the single crystals required for X-ray diffraction. NMR can provide valuable structural and dynamic information on proteins and their drug complexes that cannot be obtained with X-ray crystallography. This review discusses recent advances in NMR that have been driven by structural genomics projects. These advances suggest that the future discovery and design of drugs can increasingly rely on protocols using NMR approaches for the rapid and accurate determination of structures.
合理药物设计依赖于生物大分子的三维结构,尤其侧重于蛋白质。美国国立卫生研究院(NIH)国立综合医学科学研究所(NIGMS)的蛋白质结构计划(PSI)建立的基于结构基因组学的高通量结构测定平台特别适合提供这些结构。核磁共振(NMR)在结构测定中起着关键作用,因为许多重要的蛋白质靶点不会形成X射线衍射所需的单晶。NMR可以提供关于蛋白质及其药物复合物的有价值的结构和动力学信息,而这些信息是X射线晶体学无法获得的。本综述讨论了由结构基因组学项目推动的NMR的最新进展。这些进展表明,未来药物的发现和设计可以越来越多地依赖于使用NMR方法快速准确测定结构的方案。